NanoPortal Pipeline Overview
Nano Precision Medical has to date, generally focused on delivering GLP-1 therapies for metabolic diseases such as Type II Diabetes and Non-Alcoholic Steatohepatitis (NASH). These products, while developed for humans, also have applications and markets in other species, such as cats. In addition to the products above, NanoPortal is a platform technology, with potential applications in many disease areas.
Proven injectable type 2 diabetes treatment
High GLP-1 levels increases satiety through delayed gastric emptying.
Effective glycemic control
GLP-1 agonists enhance insulin sensitivity and insulin secretion.
Safe and effective treatment
Exenatide was first approved for treating type 2 diabetes in 2005.